1.Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA: A Cancer Journal for Clinicians, 2015, 65(1):5-29.
2.Jeon S Y, Hwang K A, Choi K C. Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development[J]. The Journal of Steroid Biochemistry and Molecular Biology, 2016: S0960076016300188.
3.Torre L A, Trabert B, Desantis C, et al. Ovarian cancer statistics, 2018[J]. CA: A Cancer Journal for Clinicians, 2018, 68(4): 284-296.
4.Xu X, Qiu J, Sun Y. The basics of CAR T design and challenges in immunotherapy of solid tumors — Ovarian cancer as a model[J]. Human Vaccines & Immunotherapeutics, 2017:1-8.
5.Kruger S, Ilmer M, Kobold S, et al. Advances in cancer immunotherapy 2019 – latest trends[J]. Journal of Experimental & Clinical Cancer Research, 2019, 38(1).
6.Whilding Lynsey M, Halim Leena, Draper Benjamin, Parente-Pereira Ana C, Zabinski Tomasz, Davies David Marc, Maher John. CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. [J]. Cancers,2019,11(5).
7.Song D G, Ye Q, Santoro S, et al. Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition[J]. Human Gene Therapy, 2013, 24(3):295-305.
8.Owens G L, Sheard V E, Kalaitsidou M, et al. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer[J]. Journal of Immunotherapy, 2018, 41.
9.Schneider D, Xiong Y, Wu D, et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines[J]. Journal for ImmunoTherapy of Cancer, 2017, 5(1):42.
10.Lanitis Evripidis, Poussin Mathilde, Klattenhoff Alex W, Song Degang, Sandaltzopoulos Raphael, June Carl H, Powell Daniel J. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivo. [J]. Cancer immunology research,2014,1(1).
11.Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape[J]. The Journal of clinical investigation, 2016, 126(8):3036-3052.
12.Wilkie S , Schalkwyk M C I , Hobbs S , et al. Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling [J]. Journal of Clinical Immunology, 2012, 32(5):1059-1070.
13.Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress[J]. Molecular Cancer, 2014, 13(1):129.
14.Liu Q, Cheng Z, Luo L, et al. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis [J]. Oncotarget, 2014, 7(24):36800-36813.
15.Taube J M , Anders R A , Young G D , et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape [J]. Science Translational Medicine, 2012, 4(127):127ra37-127ra37.
- Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment[J]. NATURE REVIEWS IMMUNOLOGY, 2008, 8(6):467-477.
- Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J]. British Journal of Cancer, 2015, 112(9):1501-1509.
18.Qu Q X, Xie F, Huang Q, et al. Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells[J]. Cellular Physiology and Biochemistry, 2017:1893-1906.
19.Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition [J]. J Clin Invest. 2016 Aug 1;126(8):3130-44. Doi: 10.1172/JCI83092. Epub 2016 Jul 25.
20.Fan C, Reader J, Roque D M. Review of Immune Therapies Targeting Ovarian Cancer[J]. Current Treatment Options in Oncology, 2018, 19(12).
21.Peng W, Liu C, Xu C, et al. PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines[J]. Cancer Research, 2012, 72(20):5209-5218.
22.Strickland K C, Howitt B E, Shukla S A, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. [J]. Oncotarget, 2016, 7(12):13587-13598.
23.Abiko K, Mandai M, Hamanishi J, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. [J]. Clinical Cancer Research, An Official Journal of the American Association for Cancer Research, 2013, 19(6):1363-1374.
24.Sui X, Ma J, Han W, et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients[J]. Oncotarget, 2015, 6(23):19393-19404.
25.Marco R, Barrett D M, Kenderian S S , et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies[J]. Journal of Clinical Investigation, 2016, 126(10):3814-3826.
26.Grosser R, Cherkassky L, Chintala N , et al. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors[J]. Cancer Cell, 2019, 36(5):471-482.
27.Feng X, Xu W, Li Z, et al. Disease Immunotherapy: Immunomodulatory Nanosystems (Adv. Sci. 17/2019)[J]. Advanced Science, 2019, 6(17).
28.Liu X , Ranganathan R , Jiang S , et al. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors[J]. Cancer Research, 2016, 76(6):1578-1590.
29.Sanchez, Eric, Smith, Emily J, Yashar, Moryel A, et al. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma[J]. Targeted Oncology. http://kns.cnki.net/kcms/detail/61.1415.R.20190903.1344.172.html.
30.Ma Futian, Ho Jin-Yuan, Du Huan, Xuan Fan, Wu Xiaoli, Wang Qinglong, Wang Lin, Liu Ying, Ba Min, Wang Yizhuo, Luo Jianmin, Li Jianqiang. Evidence of Long-Lasting Anti-CD19 Activity of Engrafted CD19 Chimeric Antigen Receptor Modified T Cells in A Phase I Study Targeting Pediatrics with Acute Lymphoblastic Leukemia.[J]. Hematological oncology,2019.
31.Li Jie, Wu Zhenyu, Zhao Naiqing. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.[J]. Advances in therapy,2019.
32.Leong, Tan, Cua, et al. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer[J]. International Journal of Molecular ences, 2020, 21(2):381.
33.Zhu X , Cai H , Zhao L , et al. CAR-T cell therapy in ovarian cancer: from the bench to the bedside[J]. Oncotarget, 2017, 8(38).
34.Teachey D T, Lacey S F, Shaw P A, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia[J]. 2016, 6(6):664-679.
35.Wang Z , Han W . Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J]. Biomarker Research, 2018, 6(1):4.
36.Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124:188–95.
37.Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017; 8:17002–17011. http:// doi.org/10.18632/oncotarget.15218.
38.Wen H, Qu Z, Yan Y, et al. Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice[J]. Annals of Translational Medicine, 2019, 7(23): 735-735.